Gene test for glaucoma risk in Egyptian adults
Part of Eyes & vision clinical trials.
This study looks at whether a specific gene change is linked to a higher risk of primary open-angle glaucoma, a common type of glaucoma. It aims to help understand why some people get this condition and could lead to earlier detection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 30 years old
- You have been diagnosed with primary open-angle glaucoma (with typical vision loss and optic nerve damage)
- Or you are a healthy person without glaucoma, matched by age and sex (for the control group)
- You do not have other types of glaucoma like exfoliation or pigmentary glaucoma
- You have no history of acute angle closure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy treatment called GVB-2001 for people with primary open angle glaucoma. It involves a one-time injection into the eye to help lower eye pressure, and could be an option if you have tried other treatments that haven't worked well enough.
This study looks at blood or DNA-related factors that may explain why certain glaucoma and related eye conditions happen. It may help researchers understand risk and causes across different glaucoma types.
This study follows people with glaucoma, higher-than-normal eye pressure, or a suspected risk of glaucoma. It aims to better understand how eye pressure and eye findings relate to glaucoma and may guide future treatment decisions.
This study tests new ways to evaluate eyes to help diagnose glaucoma and related eye conditions. You may be able to join if you’re an adult with normal eye health or with concerns like myopia, glaucoma suspicion, or ocular hypertension.
This study looks at how well your body processes clopidogrel (a blood thinner), based on your genes. It aims to see if certain gene changes affect how the medicine works for Egyptian patients after heart procedures.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
Hear when a new Primary Open Angle Glaucoma (POAG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.